DNA Polymerase Theta (POLQ) Drug Discovery Landscape & Assay Solutions
- By admin
- 25 Aug 2026
- Comments
Market Intelligence, Synthetic Lethality Strategies, and High-Purity Reagents for BRCA-Deficient Cancer Therapeutics.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for POLQ inhibitor development and synthetic lethality validation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| POLQ Polymerase Domain (aa 1790-2590) | High purity (>95%), HEK293 Expressed, Endotoxin <1EU/µg. Sequence Verified. | View POLQ Products |
| POLQ Helicase Domain | High purity (>95%), HEK293 Expressed, Endotoxin <1EU/µg. Sequence Verified. | View POLQ Products |
| Gene Delivery | POLQ Promise-ORF Lentivirus (full-length ORF, >10^8 TU/ml) for stable overexpression in BRCA-deficient cell lines. | View POLQ Products |
| Benchmark Ab | Anti-POLQ (Research Grade) for Target Engagement & Pharmacodynamic (PD) assays (Western Blot/IHC). | View POLQ Products |
| Validator | POLQ siRNA Set (3 unique sequences) for synthetic lethality validation and specificity controls. | View POLQ Products |
| Related Target: BRCA1 | BRCA1 WT & Mutant Proteins; synthetic lethal partner for combination screening. | View BRCA1 Products |
| Related Target: PARP1 | PARP1 / PARP2; parallel synthetic lethal pathway; comparator for combination studies. | View PARP1 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Domain-Specific Inhibition Analysis (Helicase vs Polymerase) | Separate high-purity recombinant Helicase and Polymerase domains for distinct enzymatic screening. |
| Polymerase Selectivity Screening (Off-target: Pol η, β, γ) | Homologous DNA Polymerase Panel (Pol η, Pol β, Pol γ) with >95% purity; Sequence Verified for accurate selectivity profiling. |
| Drug Resistance Mutation Profiling | Mutant POLQ Proteins (Predicted resistance sites: D1884, Y1893 in polymerase domain); Theoretical MW confirmed by Mass Spec. |
| Synthetic Lethality Validation (including false-positive control) | High-titer Lentivirus (>10^8 TU/ml) for stable POLQ knockdown/overexpression; Sequence-verified siRNA for precise genetic validation. |
| Target Engagement Assay | High-affinity Anti-POLQ Antibody for Cellular Thermal Shift Assay (CETSA) and Western Blot validation. |
Live POLQ R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for POLQ therapeutics is intensifying, with major players advancing first-in-class small molecule inhibitors through Phase I/II trials. As synthetic lethality strategies mature beyond PARP inhibitors, POLQ has emerged as a critical vulnerability in BRCA1/2-deficient, PALB2-mutant, and other homologous recombination-deficient (HRD) tumors. The next wave of R&D is targeting combination regimens with PARP inhibitors to overcome resistance, resistance mutation profiling, and expansion into CNS malignancies where BRCA deficiencies are prevalent. PROTAC degraders are also emerging as a novel modality to eliminate both helicase and polymerase functions simultaneously.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Polymerase Domain) | AstraZeneca (AZD7648), Artios (ART4215), Repurposed antibiotics (Novobiocin) | BRCA-mutant Ovarian, Breast, Prostate Cancers; HR-Deficient Solid Tumors | Biochemical Polymerase Activity Assay (Need high-purity catalytic domain) |
| Small Molecule (Helicase Domain) | Ideaya (IDE161), Artios | BRCA-Mutated Breast/Ovarian Cancer | ATPase Assay (Need high-purity Helicase domain) |
| Synergistic Combination (PARPi + POLQi) | Multiple Academic/Industry | PARPi-resistant tumors | Synthetic Lethality Cell Assay (Need validated siRNA & Isogenic cell lines) |
| PROTAC / Degrader | Emerging Biotech | Refractory Cancers | Degradation Validation (Need specific benchmark Abs & Lentivirus) |
Key Considerations for Drug Discovery
- Selectivity: Best-in-class inhibitors must achieve >100-fold selectivity over other DNA polymerases (Pol γ, Pol ν, etc.) to avoid mitochondrial toxicity. TarMart provides a full panel of sequence-verified homolog proteins.
- Cross-species reactivity: For in vivo efficacy and toxicology, compounds need consistent activity against mouse, dog, and monkey POLQ orthologs. TarMart's recombinant proteins are available for multiple species.
- Resistance profiling: Anticipating acquired resistance mutations (e.g., D1884A, Y1893F in the polymerase domain) is critical. TarMart offers custom mutant protein services with full gene sequencing verification.